Dova Pharmaceuticals Inc (NASDAQ:DOVA) shares shot up 5.9% during mid-day trading on Friday . The stock traded as high as $31.97 and last traded at $31.85. 880,500 shares changed hands during trading, an increase of 325% from the average session volume of 207,292 shares. The stock had previously closed at $30.07.
Several research firms have recently issued reports on DOVA. BidaskClub downgraded Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. Evercore ISI began coverage on shares of Dova Pharmaceuticals in a research note on Friday, March 23rd. They issued a “line” rating and a $29.00 target price for the company. ValuEngine raised shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Zacks Investment Research raised shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 14th. Finally, LADENBURG THALM/SH SH began coverage on shares of Dova Pharmaceuticals in a research note on Thursday, April 26th. They issued a “buy” rating for the company. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Dova Pharmaceuticals has an average rating of “Buy” and an average target price of $32.00.
Dova Pharmaceuticals (NASDAQ:DOVA) last announced its earnings results on Wednesday, May 9th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.05). equities analysts forecast that Dova Pharmaceuticals Inc will post -2.18 earnings per share for the current year.
In other Dova Pharmaceuticals news, major shareholder Life Sciences Maste Perceptive purchased 10,000 shares of the stock in a transaction on Monday, June 4th. The stock was bought at an average price of $25.07 per share, for a total transaction of $250,700.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Paul B. Manning purchased 27,000 shares of the stock in a transaction on Thursday, June 7th. The stock was acquired at an average price of $28.42 per share, with a total value of $767,340.00. The disclosure for this purchase can be found here. Insiders purchased a total of 301,700 shares of company stock valued at $8,319,082 in the last three months. 55.50% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its holdings in Dova Pharmaceuticals by 148.6% in the 1st quarter. JPMorgan Chase & Co. now owns 5,345 shares of the company’s stock valued at $145,000 after buying an additional 3,195 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in Dova Pharmaceuticals by 36.4% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 13,500 shares of the company’s stock valued at $367,000 after buying an additional 3,600 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Dova Pharmaceuticals by 702.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 4,756 shares of the company’s stock valued at $137,000 after buying an additional 4,163 shares during the period. Deutsche Bank AG grew its holdings in Dova Pharmaceuticals by 139.2% in the 4th quarter. Deutsche Bank AG now owns 11,748 shares of the company’s stock valued at $337,000 after buying an additional 6,836 shares during the period. Finally, Jane Street Group LLC purchased a new stake in Dova Pharmaceuticals in the 1st quarter valued at about $220,000. Institutional investors own 35.93% of the company’s stock.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.